Consistent with this pattern, our study also revealed that serum sST2 concentrations were significantly higher in ovarian cancer patients compared with the control group, suggesting that activation of the IL-33/ST2 axis may contribute to the pathogenesis of ovarian cancer. The gene discussed is IL33; the disease is ovarian carcinoma.